Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GrifolsWBO:GRF -0.85%85 Days Payable is 78.07 as of Jun. 2026, which is 7% above its 10-year median of 72.66. GuruFocus rates WBO:GRF with a GF Score™ of 85/100 and a GF Value™ of €10.92. The stock has 7 warning signs investors should review. Among 926 Drug Manufacturers companies, Grifols ranks worse than 62.53% on this metric.
Grifols's average Accounts Payable for the
three
months ended in Jun. 2026 was €1,001 Mil. Grifols's Cost of Goods Sold for the
three
months ended in Jun. 2026 was €1,170 Mil.
Hence, Grifols's Days Payable for the
three
months ended in Jun. 2026 was 78.07.
The historical rank and industry rank for Grifols's Days Payable or its related term are showing as below:
WBO:GRF'
s Days Payable Range Over the Past 10 Years
Min: 66.23 Med: 72.66 Max: 75.7
Current: 70.78
During the past 13 years, Grifols's highest Days Payable was 75.70. The lowest was 66.23. And the median was 72.66.
WBO:GRF's Days Payable is ranked worse than 62.53% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs WBO:GRF: 70.78
Grifols's Days Payable
increased
from Jun. 2025 (69.88) to Jun. 2026 (78.07).
It may suggest that Grifolsdelayed paying its suppliers.
The historical data trend for Grifols's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:GRF vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Grifols's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's Days Payable distribution charts can be found below:
* The bar in red indicates where Grifols's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Grifols's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (WBO:GRF) has a Days Payable of 78.07 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Grifols and its competitors. This is near median its historical median of 72.66. Over the past decade, Grifols' Days Payable has ranged from 66.23 to 75.70. According to the industry distribution chart, Grifols ranks #579 out of 926 companies in the Drug Manufacturers industry, placing it in the top 62.5%.
Is Grifols' Days Payable too high?
Grifols' current Days Payable of 78.07 is near median its 10-year median of 72.66. Over the past 10 years, this metric has ranged from a low of 66.23 to a high of 75.70. The Drug Manufacturers industry median Days Payable is 90.22. Grifols' value of 78.07 is 13.5% below this industry median. Based on the distribution chart, Grifols ranks #579 out of 926 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Grifols has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #579 out of 926 companies for Days Payable. This places Grifols in the lower half of its industry. The industry median Days Payable is 90.22. Grifols' value of 78.07 is 13.5% below this benchmark. Historically, Grifols' own Days Payable has ranged from 66.23 to 75.70 over the past decade. While the company's 10-year median is 72.66 vs. the industry median of 90.22, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Days Payable of 78.07 is 13.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Days Payable is 78.07, which is near median its own 10-year median of 72.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (WBO:GRF) has a current Days Payable of 78.07. The stock's GF Value™ is €10.92, compared to a current price of €10.53 — trading 3.6% below its estimated fair value. The current Days Payable is 78.07, which is near median its 10-year median of 72.66 and 13.5% below the Drug Manufacturers industry median of 90.22. Grifols' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Grifols (WBO:GRF), the current Days Payable is 78.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (WBO:GRF) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of €10.53 is trading 3.6% below its estimated GF Value™ of €10.92.
Key valuation signals for WBO:GRF:
Days Payable: 78.07 (near median its 10-year median of 72.66)
GF Value™: €10.92 vs. price of €10.53 (3.6% below fair value)
Industry Position: 13.5% below the Drug Manufacturers median (#579 of 926)
No single metric tells the full story. See the WBO:GRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
85GF Score
Get the complete analysis for WBO:GRF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:GRF has been successfully added to your 
